Alnylam's HELIOS-A Trial Meets Secondary Endpoints At 18 Months; Vutrisiran Faces FDA On Apr.14

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc.'s (ALNY) phase III trial of investigational RNAi therapeutic Vutrisiran in patients with hATTR amyloidosis with polyneuropathy has met all secondary

Related Keywords

Washington ,United States ,Ionis Tegsedi ,Alnylam Onpattro ,Alnylam Pharmaceuticals Inc ,Neuropathy Impairment Score ,Norfolk Quality ,Life Questionnaire Diabetic Neuropathy ,Alnylam ,Helios ,Trial ,Meets ,Secondary ,Endpoints ,Months ,Vutrisiran ,Races ,